DJIA 17,712.66 34.43 0.19%
NASDAQ 4,891.22 27.86 0.57%
S&P 500 2,061.02 4.87 0.24%
market minute promo

TAKEDA PHARM CO LTD S/ADR (NASDAQOTH: TKPYY)

25.68 -0.42 (-1.61%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

TKPYY $25.68 -1.61%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $25.59
Previous Close $26.10
Daily Range $25.57 - $25.70
52-Week Range $20.36 - $27.52
Market Cap $40.6B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.6%)
Volume 18,980
Average Daily Volume 28,616
Current FY EPS $0.56

Sector

Industry

TAKEDA PHARM CO LTD S/ADR (TKPYY) Description

Website:

News & Commentary Rss Feed

Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch

Fourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.

Forget About Ebola Stocks and Invest in This Instead

Instead of Ebola drugmakers, investors may be better served focusing on these healthcare trends.

Which Biotech Stock Should Pfizer, Inc. Buy?

Motley Fool contributors offer up three potential acquisition targets for Pfizer.

Newly Approved Weight Loss Method Works by Tricking Your Brain

What's the best way to lose weight? One company thinks it's simple: don't get hungry.

Why Seattle Genetics, Inc. Stock Dove 12% in December

Seattle Genetics' shares get hammered following impressive clinical data from its rivals at the American Society of Hematology's annual meeting. Find out whether this dip represents a buying opportunity or a red flag.

Buying These 3 Stocks Is Like Making a Bet in a Burning House

Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?

Is Sunesis Pharmaceuticals Poised for a Breakout?

The little-known biopharma Sunesis Pharmaceuticals is on the cusp of unblinding late-stage trial data for its flagship oncology drug vosaroxin. Leading into this seminal event, management sounds fairly confident of a positive result, but the market clearly has its doubts. Why?

Today’s Top Biotech Stories: Takeda, Eli Lilly, Immunomedics, and Pharmacyclics

Takeda, Eli Lilly, Immunomedics, and Pharmacyclics could loom large in health care headlines this Tuesday morning.

Orexigen Therapeutics Reduces Q4 Loss by 34%

Lower research and development expenses help lower Orexigen's quarterly loss.

Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?

A number of factors are holding back obesity therapies, but this one glimmer of light has the potential to change that perception.

See More TKPYY News...